FINWIRES · TerminalLIVE
FINWIRES

$RPRX

5 stories mentioning RPRXUpdated 8d ago

Every FINWIRES story that references RPRX, newest first.

Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) marginally advancing.Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at $1.5 billion, the companies said. Shares of Repligen were down more than 4% and BioLife Solutions stock was up more than 2% pre-bell.Royalty Pharma (RPRX) said it will pay up to $425 million, including a $125 million upfront payment, to Neurimmune for a 3% to 4% royalty on worldwide net sales of its interest in AstraZeneca's (AZN) cliramitug. Royalty Pharma stock was down more than 1% pre-bell.Healthcare Services Group (HCSG) shares were 0.8% higher after the company reported that it swung to a Q2 net income as revenue increased during the period.

$AZN$BLFS$HCSG$IBB$RGEN$RPRX$XLV
Insider Trading

Royalty Pharma Insider Sold Shares Worth $8,159,277, According to a Recent SEC Filing

Christopher Hite, Executive Vice President & Chairman, Partnering, on June 23, 2026, sold 150,000 shares in Royalty Pharma (RPRX) for $8,159,277. Following the Form 4 filing with the SEC, Hite has control over a total of 629,399 Class A ordinary shares of the company, with 70,000 shares held directly and 559,399 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000181423826000009/xslF345X05/wk-form4_1782421910.xml

$RPRX
Insider Trading

Royalty Pharma Insider Sold Shares Worth $502,067, According to a Recent SEC Filing

Marshall Urist, Executive Vice President, Research & Investments, on June 24, 2026, sold 9,098 shares in Royalty Pharma (RPRX) for $502,067. Following the Form 4 filing with the SEC, Urist has control over a total of 9,099 Class A ordinary shares of the company, with 9,099 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000183813926000020/xslF345X05/wk-form4_1782422032.xml

$RPRX
Insider Trading

Royalty Pharma Insider Sold Shares Worth $3,476,116, According to a Recent SEC Filing

Terrance P. Coyne, Executive Vice President & CFO, on May 26, 2026, sold 64,399 shares in Royalty Pharma (RPRX) for $3,476,116. Following the Form 4 filing with the SEC, Coyne has control over a total of 50,390 Class A ordinary shares of the company, with 1,500 shares held directly and 48,890 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000181487626000022/xslF345X05/wk-form4_1780001297.xml

$RPRX
Insider Trading

Royalty Pharma Insider Sold Shares Worth $1,731,840, According to a Recent SEC Filing

Terrance P. Coyne, Executive Vice President & CFO, on April 28, 2026, sold 34,791 shares in Royalty Pharma (RPRX) for $1,731,840. Following the Form 4 filing with the SEC, Coyne has control over a total of 90,526 Class A ordinary shares of the company, with 1,500 shares held directly and 89,026 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1802768/000181487626000018/xslF345X05/wk-form4_1777586044.xml

$RPRX

Track with the FINWIRES app suite

FolioX
FolioX
Track RPRX in your portfolio
WheelAI
WheelAI
Analyze RPRX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on RPRX